Endonovo Therapeutics, Inc. (ENDV) stock
ENDVOTCElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Financials through Q3 FY2023, quarter ended Sep 30, 2023Last filing: 10-Q/A on Dec 29, 2023
$0.00+0.00 (0.00%)
Close on Oct 19, 2026Market cap $135.08KP/E –Yield –
Endonovo Therapeutics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Endonovo Therapeutics's price to sales ratio was 0.1× on Oct 19, 2026, against 0.2× a year earlier. Over the last 5 years it ranged from 0.0× to 210.7×, with a median of 3.1×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Oct 19, 2026 | 0.1× | +0.0 |
| 2025 | Dec 31, 2025 | 0.1× | −0.4 |
| 2024 | Dec 31, 2024 | 0.5× | −10.3 |
| 2023 | Dec 29, 2023 | 10.8× | −190.9 |
| 2022 | Dec 30, 2022 | 201.7× | +188.9 |
| 2021 | Dec 31, 2021 | 12.8× | +11.7 |
| 2020 | Dec 31, 2020 | 1.1× | −58.9 |
| 2019 | Apr 30, 2019 | 60.1× | – |
See a number that looks wrong?